

A novel treatment for the pain of osteoarthritis.

Cingal® is the first and only approved combination viscosupplement formulated to provide the benefit of a cross-linked hyaluronic acid and a fast acting steroid.

From the makers of Orthovisc® and Monovisc®, Cingal is formulated for a single-injection regimen comprised of triamcinolone hexacetonide (TH) steroid and a high molecular weight, lightly crosslinked hyaluronic acid (HA).

THE CINGAL DIFFERENCE

Cingal is a powerful, first in class treatment that combines the proven benefits of Anika's proprietary high concentration cross-linked hyaluronic acid formulation, approved for long-term pain relief, with well-established FDA-approved steroid to treat inflammation.

CINGAL DELIVERS

In a study of the effectiveness of Cingal compared to a leading HA viscosupplement and saline, Cingal was superior to saline through 26 weeks in WOMAC pain score delivering a 72% improvement relative to baseline.¹ Cingal provided statistically significant faster pain relief compared to HA without a steroid in weeks one and three.¹

THE CINGAL BENEFITS

- Fast acting pain relief, within days of injection
- Long lasting pain relief through six months
- Convenient single-injection treatment
- Highly concentrated, non-animal based HA
- Safe and effective

THE SCIENCE BEHIND CINGAL

Micronized particles of the water-insoluble steroid are suspended in the viscoelastic HA gel and reside within Cingal as a separate solid phase. Both the HA and steroid remain unchanged by incorporation into the Cingal formulation and by sterilization.²



About Cingal®



Description

Cingal is a novel combination HA plus steroid single-injection treatment for the pain associated with osteoarthritis. Cingal combines the high molecular weight cross-linked hyaluronic acid (HA) formulation of Monovisc® with a corticosteroid for additional short-term pain relief.

Indications

Cingal is indicated as a viscoelastic supplement or a replacement for synovial fluid in human knee joints. Cingal is well suited for rapid and long term relief of the symptoms of human knee joint dysfunctions such as osteoarthritis.³ The actions of Cingal are long term relief of symptoms by lubrication and mechanical support supplemented by short-term pain relief provided by triamcinolone hexacetonide.

Directions For Use

The pre-filled syringe is intended for single use only. The contents of the syringe should be used immediately after opening. Discard any unused Cingal. Do not resterilize.

Store Cingal at 2 to 25°C. Protect from freezing. Refrigerated Cingal should be allowed to reach room temperature (approx. 20-45 min.) prior to use.

Only medical professionals trained in accepted injection techniques for delivering agents into the knee joint should inject Cingal for the indicated use.

Contents

The product contains 22 mg/mL high molecular weight cross-linked hyaluronic acid produced from bacterial fermentation, 4.5 mg/mL triamcinolone hexacetonide.

How Supplied

Cingal is supplied as a 4 mL unit dose in a terminally-sterilized 5 mL glass syringe

Refer to the Instructions for Use for complete product information



REFERENCES

1. Hangody L, et al. Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee. *Cartilage* 2017 May; doi: 10.1177/1947603517703732.

2. Anika data on file

3. CINGAL Instructions for Use. EU. AML 500-277

Anika Therapeutics, Inc.
32 Wiggins Ave, Bedford, MA USA
www.anikatherapeutics.com

©2020 Anika Therapeutics, Inc. | 06/20 | AML 900-067/B
Anika, Cingal, Monovisc, and Orthovisc are registered trademarks of Anika Therapeutics, Inc.
The information contained in this document applies exclusively to territories outside of the USA

